Pfizer, a pharmaceutical company, has recently divested its entire ownership in Haleon for approximately 2.5 billion pounds ($3.24 billion) to institutional investors and the consumer healthcare firm. This transaction was done at a price of 385 pence per share. As part of the agreement, Haleon, known for brands like Sensodyne, will repurchase 44 million shares from Pfizer, its biggest shareholder, and 618 million shares will be sold to institutional investors.

The sale of Pfizer's holdings accounts for 7.3% of Haleon's issued share capital. Haleon was established through the merger of GSK and Pfizer's consumer healthcare divisions in 2019 and was later separated from the British drugmaker in 2022. GSK, which previously held nearly 13% of Haleon, divested its entire ownership in May 2024.

Following the divestment by Pfizer, BlackRock Investment Management (UK) Ltd, a subsidiary of BlackRock, will be the largest shareholder in Haleon holding over a 5% stake. The share sale is being managed by global coordinators such as BofA Securities, Citigroup Global Markets Limited, and Goldman Sachs International, with Barclays and Deutsche Numis as joint bookrunners.

In addition to Sensodyne, Haleon manufactures pain relievers like Panadol and Advil. In February, the company announced that its revenue and profit growth targets for 2025 are expected to be more prominent in the latter part of the year. The information was reported by Anandita Mehrotra from Bengaluru, and edited by Mrigank Dhaniwala.